Valuation: Tenax Therapeutics, Inc.

Market Cap 790M 690M 634M 591M 1.12B 75.2B 1.14B 7.63B 2.96B 36.88B 2.97B 2.9B 127B P/E 2026 *
-10.8x
P/E 2027 * -11.1x
Enterprise Value 790M 690M 634M 591M 1.12B 75.2B 1.14B 7.63B 2.96B 36.88B 2.97B 2.9B 127B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.88%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day+16.33%
1 week+19.94%
Current month+6.25%
1 month+41.19%
3 months+2.96%
6 months+39.91%
Current year+26.83%
1 week 12.96
Extreme 12.96
15.49
1 month 10.25
Extreme 10.25
15.49
Current year 10.25
Extreme 10.25
18.38
1 year 5.68
Extreme 5.6843
18.38
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,280
10 years 2.77
Extreme 2.77
88,640
Manager TitleAgeSince
Chief Executive Officer 52 2021-07-13
Director of Finance/CFO 58 2026-05-10
Chief Tech/Sci/R&D Officer - 2025-01-20
Director TitleAgeSince
Chairman 67 2021-05-31
Director/Board Member 76 2021-02-24
Director/Board Member 69 2021-02-24
Date Insider Type Main position Quantity % Market Cap.
05-10Free

Chief Financial Officer

460,000 2.6748%
05-10Other

Chief Financial Officer

0 0%
01-29Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
+16.33%+19.94%+169.34%-35.58% 679M
+0.36%+5.10%+1.04%+5.85% 48.62B
+0.92%+6.21%+408.85%+607.44% 39.86B
+1.89%+11.06%+25.75%-7.89% 33.91B
+2.38%+8.10%+21.83%+66.94% 32.32B
+1.20%+2.02%+9.79%+32.43% 24.73B
+2.51%+4.94% - - 16.63B
+2.58%+7.24%+71.03%+132.17% 15.52B
+0.99%+1.26%+13.98%+18.88% 13.63B
-1.14%+7.52%+14.75%-30.83% 13.41B
Average +2.80%+6.20%+81.82%+87.71% 23.93B
Weighted average by Cap. +1.32%+6.99%+88.80%+130.53%

Financials

2026 *2027 *
Net sales - -
Net income -79.71M -69.65M -63.96M -59.64M -113M -7.59B -115M -770M -298M -3.72B -299M -293M -12.82B -93.97M -82.11M -75.4M -70.31M -133M -8.95B -136M -908M -352M -4.39B -353M -345M -15.12B
Net Debt - -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
26-07-02 US$15.46 +16.33% 3,893,351
26-07-01 US$13.29 -8.66% 827,284
26-06-30 US$14.55 +7.78% 1,330,632
26-06-29 US$13.50 +0.45% 648,504
26-06-26 US$13.44 +4.27% 5,207,904
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.46USD
Average target price
33.88USD
Spread / Average Target
+119.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock